Schedule 13G ownership disclosure

Acumen Pharmaceuticals, Inc.

Common Stock, par value $0.0001 per share · CUSIP: 00509G209

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Sands Capital Alternatives, LLC

    Shares: 3,417,075.00 · Class: 5.6%

  • Sands Capital Ventures Discovery Fund III, L.P.

    Shares: 1,124,729.00 · Class: 1.9%

  • Sands Capital Global Venture Fund II, L.P.

    Shares: 1,146,173.00 · Class: 1.9%

  • Sands Capital Life Sciences Pulse Fund, LLC

    Shares: 1,146,173.00 · Class: 1.9%

  • SANDS FRANK M.

    Shares: 3,417,075.00 · Class: 5.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001846444-25-000017
Form type
SCHEDULE 13G/A
Filer
Acumen Pharmaceuticals, Inc.
CIK
CIK 1576885
Filed
Aug 13, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub